iECURE

iECURE is a biotechnology startup that leverages disruptive gene-editing technology to treat rare, monogenic liver diseases. The company's innovative approach involves the use of in vivo insertion methods to introduce healthy copies of disease-causing genes into patients, providing long-term, stable expression of these genes. This essentially means that they replace faulty genes with healthy ones in a patient's body, potentially curing the disease.

iECURE's primary focus is on "loss of function" liver disorders, which are diseases caused by unhealthy genes with multiple disease-driving mutations. These diseases affect tens of thousands of patients worldwide, and iECURE's mission is to find cures for them.

The company collaborates closely with the University of Pennsylvania's Gene Therapy Program, a leading institution in the field of gene therapy research. This partnership forms the backbone of iECURE's early research and development initiatives.

iECURE's business model revolves around the development and commercialization of its gene-editing therapies. The company recently secured a significant financial boost, raising $65 million to advance its in vivo gene editing programs for the treatment of rare pediatric liver diseases.

Furthermore, the European Commission has granted Orphan Designation for iECURE's lead product candidate GTP-506 for the treatment of Ornithine Transcarbamylase (OTC) Deficiency. This designation is given to drugs intended for the treatment of rare diseases, providing certain benefits and market exclusivity for a period after approval.

The company is led by a management team with extensive experience in biotechnology, rare disease, and gene therapy. The recent appointment of Dr. Gabriel M. Cohn as Chief Medical Officer further strengthens the company's leadership.

Keywords: Biotechnology, Gene Editing, In Vivo Insertion, Liver Diseases, Rare Diseases, Gene Therapy, University of Pennsylvania, Orphan Designation, GTP-506, Pediatric Liver Diseases.